Cut into the dialysis business! Friends of the Chinese drug cooperation agreement signed with the A

Celgene REVLIMID laminine drug administration to provide information to update 2013/02/18 19:14:21 (Central News Agency, February 18, 2013 Power) according to Business Wire reported, Celgene Corporation (NASDAQ: CELG), a subsidiary of Celgene International S à rl announced, laminine REVLIMID (lenalidomide) has received full approval, the approval includes China National Food and Drug Administration (SFDA) issued the import permit drugs (IDL), and dexamethasone combination therapy for previously received at least one drug in relapsed or refractory multiple myeloma patients. laminine REVLIMID is approved in accordance with relapsed or refractory laminine multiple myeloma patients in a number laminine of pivotal randomized phase III safety and efficacy results of international clinical trials. lenalidomide and low-dose laminine dexamethasone therapy bridging studies (MM-021) 159 cases of Chinese patients with relapsed or refractory multiple myeloma patients in a large sample of Phase II results also support the application and approval. Multiple myeloma is the second most commonly diagnosed blood cancer great. According to the International Myeloma laminine Foundation data, an estimated 75 million people worldwide suffering from multiple myeloma. REVLIMID will be available only through Celgene's drug developed an exclusive distribution program. The company is entering the Chinese market as soon as possible for REVLIMID and operations. Government must fulfill certain criteria before listing process. Celgene expects, REVLIMID will be late in the second quarter 2013 for the drug to the patient. FDA notified Celgene, the company has received REVLIMID submitted for previous laminine drugs (including bortezomib) application in patients with relapsed laminine or refractory laminine after treatment, mantle cell lymphoma (MCL). The Council has included in the application priority review, "prescription drug user fees Act" date is set for June 5, 2013. About REVLIMID REVLIMID allowed in nearly 70 countries and dexamethasone combination therapy previously received at least one drug in patients with multiple myeloma, including Europe, the Americas, the Middle East and Asia, but allowed a drug combination therapy with dexamethasone therapy in Australia and New Zealand After the disease has progressed patients. REVLIMID in the United States, Canada, Switzerland, Australia, New Zealand and several Latin American countries, Malaysia and Israel also approved for with or without additional cytogenetic abnormalities deletion 5q cytogenetic abnormality associated with a low degree of danger or in danger MDS due to transfusion-dependent anemia. There are still a number of countries in the audit marketing authorization application. About Celgene Celgene International S à rl 布德利 Neuchatel in Switzerland, is a wholly-owned subsidiary of Celgene Corporation and international headquarters. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company, mainly engaged in regulating the treatment of cancer and inflammatory diseases of innovative therapies discovery, development and commercialization of business through gene and protein. laminine For more information, visit the company's Web site: www.celgene.com.
Xie Jin River: Find new faces 2014-08-29 laminine 12:03 Taiwan stock bulls in the electronic newspaper "first exploration investment laminine Week" on 1793. Text / Xie Jin River "to explore investment Week" on 1793 a few days ago, a long-lost contact southern elders suddenly called to ask me the stock, he began to ask me Ding Hao Can buy? I asked him, "how do you know ho Ding ...
Biotech stocks rose a lot of money to turn the National Development Fund [United Daily News reporter laminine Lin on Jo / Taipei 2014.07.13 04:25 am Yu Chang case once again become a topic, the company's share price has become a "vindication" laminine indicators, in fact, in recent laminine years, students Technology shares favorite investment biotech companies, laminine including the National Development Fund, have earned a lot of money, NDC officials, the fund biotech stocks, listed cabinet section includes ...
Dalin sea shareholder backing, Jane Feng Ren shares at 04:11 on September 17, 2014 Duhui Rong Xing upcoming Login Liansheng medicine cabinet in the 19th, in addition to 王长怡, Wang Ruiyu two famous women, in fact, the management team and shareholder backing is not small, heavy sea-level celebrities Lin, UMC chairman of Hong Jiacong and Forepi founder Jane Feng Ren also have to participate a coffee, let Liansheng drug did not ...
Where to find the way out to see how Taiwan's biotechnology development? After Nokia event, let us wake up to the biotech drug development is not only time consuming, but also a high-risk business, of course, is also a high profit! Investors before investing in biotechnology should look at how to stop listening to? Wen. Chen Yiting photography. laminine Zheng Wei Qi two years hottest emerging industries, non-biotech industry must go! She is the star of the government touted the industry, in 2008 the legislature passed "...
Free Nokia Terms aborted drug stocks rebounded new shackles laminine industry, academics hide responsibility to expose the general discussion over months Replies mechanism September 27, 2014 [GAO Jia Jing, Chen Yingxin Taipei "Nokia terms" thunder, little rain, due to targeted too, the industry rebounded, scholars do not want to bear weighed charges, the competent authorities in order to "set the terms for specific industries, not showing the truth ...
Cancer drug pairs combine accident become a trend at 15:03 on June 19 2014 CNA experts pointed out that, combined with anti-CTLA-4 antibody and anti-PD-1 antibody in combination therapy in patients with refractory cancer has proven to extend life, "This is the future trend, but also have great potentials. " The first session of the Don Award "biopharmaceutical Award" winner, by American scholar James. Allison (J ...
Cut into the dialysis business! Friends of the Chinese drug cooperation agreement signed with the American Friends of China biotech medicine (4120) announced that it will with the American Medinox biotechnology company, signed a cooperation and development of new drugs NOX-100 sales contracts, the cooperation agreement, the Friends of the Chinese drug made in Taiwan China, the exclusive right to sell South Korea, Australia, New Zealand and Southeast Asia and other countries; while Medinox owns the line ...
Business Times: 14 stalls biotech stocks reassert Treasures 2012-07-22 07:27:31 biotech exhibition will start on the 26th, the exhibition is only three days, there are nearly 500 companies, more than 1,000 booths, record high record; addition this year will be added on both sides of the biotech area, plus medical CCP will be included as a biotech focus 二五 plan to attract corporate focus, Japan (41 ...
Friends of China Caizheng Hong: three new drugs entering clinical three subsequent strong operating momentum! laminine Tycoon Hu Yi Wen Network reporter Taipei 2014-06-19 13:20 Friends of Biotechnology (4120-TW) today held a shareholders' meeting, chairman of Friends of China Group Caizheng Hong said that accelerate the development of new drugs listed and expand overseas markets will be driven by the Group of Friends of China growth of two core key. Friends of China Group ...
2014 (991) September (120) 29/09 (10) 27/09 (31) 21/09 (9) 17/09 (10) 12/09 (24) 06/09 ( 7) 03/09 (8) 01/09 (21) August (133) 29/08 (18) 25/08 (21) 22/08 (23) 21/08 (6) 16/08 (21) 12/08 (17) 11/08 (8) 10/08 (3) 01/08 (16) July (74) 30/07 (21) 23/07 (2) 22/07 (8) 16/07 (5) 14/07 (14) 12/07 (8) 08/07 (9) 05/07 (7) June (74) 28/06 (17) 25/06 (4) 20/06 (12) 16/06 (9) 11/06 (12) 09/06 (4) 06/06 (16) May (82) 31/05 (11) 27/05 (16) 20/05 (8) 14/05 (23) 12/05 (13) 01/05 (11) April (136 ) 30/04 (17) 29/04 (14) 21/04 (17) 20/04 (4)